^
Association details:
Biomarker:LRP1B mutation
Cancer:Prostate Cancer
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Excerpt:
The most common ICIs were pembrolizumab (29/44, 66%) and nivolumab (12/44, 27%)....Among pts with LRP1b PVs, 36% (95%CI 14%-64%) had radiographic responses (5/14, 2 lung, 1 prostate, 1 RCC, 1 endometrial carcinoma), two of whom were MSI high....The majority of responders were MSS and TMB low, which may suggest that PV in LRP1B may independently predict for response to ICI.
DOI:
10.1200/JCO.2019.37.15_suppl.e14291
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer

Excerpt:
...the prevalence of LRP1b mutations in our cohort was 22% (4/18), and the response to pembrolizumab (PSA decline ≥50%) in this genomic subset was 75%...with duration of response ranging from 4.6 to 16.3 months. Among men with genomic profiling not revealing mutations in LRP1b, the response to pembrolizumab (PSA decline ≥50%) was 14% (2/14), with duration of response ranging from 0.7 to 4.2 months.
DOI:
10.1002/cam4.2375